FibroGen Reports Second Quarter 2023 Financial Results
August 07, 2023 16:01 ET
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
Harbert Management Corporation Announces Head of Infrastructure and Senior Managing Director
February 16, 2023 13:41 ET
|
Harbert Management Corporation
BIRMINGHAM, Ala., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Harbert Management Corporation (“HMC”) announces the promotion of Claude Estes to Head of Infrastructure and Senior Managing Director. In his new...
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
February 04, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...
Harbert Infrastructure Expands Investment Team, Adds Energy Storage Specialist
November 01, 2021 16:15 ET
|
Harbert Management Corporation
BIRMINGHAM, Ala., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Harbert Infrastructure is pleased to announce that it has hired Adam Nygaard as a Vice President, Investments. Mr. Nygaard joins Harbert...
FibroGen to Present at Upcoming Investor Conferences
May 27, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 08, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
November 04, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine
October 07, 2019 17:57 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company’s Scientific Advisory Board, has been...
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
September 26, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
September 20, 2019 03:05 ET
|
FibroGen, Inc; Astellas Pharma Inc.
SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji...